CureVac N.V. (CVAC) Tuesday announced that it has initiated phase 2a clinical trial of its COVID-19 vaccine candidate.
The clinical-stage biopharmaceutical company said the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CvnCoV.
The dose-confirmation study, entitled CV-NCOV-002, is being conducted in Peru and Panama and will enroll a total of 690 healthy participants.
The participants will receive two vaccinations at intervals of 28 days. Different dose levels will be investigated with the aims to confirm safety and evaluate reactogenicity of the vaccine in older adults.
First comprehensive data of Phase 2a in older adults are expected later in the fourth quarter 2020.
The study design was coordinated with and approved by the health authorities and ethics committees of Peru and Panama and is based on preliminary safety and immunogenicity data from CureVac's ongoing Phase 1 CV-NCOV-001 study in healthy adult volunteers in Germany and Belgium.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.